Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
Received 10 November 2018
Accepted for publication 10 February 2019
Published 12 April 2019 Volume 2019:13 Pages 1177—1178
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Qiongyu Guo
Leticia Orsatti, Josep Fortea, Manuel Quaresma
Boehringer Ingelheim International GmbH, Ingelheim, Germany
We read with interest the study by Abe et al on the clinical utility of nintedanib in patients with severe idiopathic pulmonary fibrosis (IPF).1 Based on the retrospective follow-up of 51 patients, the authors concluded that the survival benefit from nintedanib is reduced among patients with severe IPF (n=17) compared with those with mild-to-moderate IPF (n=34), but that the prognosis for patients with severe IPF is significantly better in those who remain on nintedanib for more than 3 months.
In our opinion, the study design does not allow conclusions to be drawn about the treatment effect of nintedanib on survival in patients with severe versus mild-tomoderate IPF.
View the original paper by Abe and colleagues
A Letter to the Editor has been received and published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]